These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36719467)

  • 41. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses.
    Pacheco-Olvera DL; Saint Remy-Hernández S; García-Valeriano MG; Rivera-Hernández T; López-Macías C
    Arch Med Res; 2022 Nov; 53(7):694-710. PubMed ID: 36336501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Profiling CD8
    Zhang H; Deng S; Ren L; Zheng P; Hu X; Jin T; Tan X
    Cell Rep; 2021 Sep; 36(11):109708. PubMed ID: 34506741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein.
    Jiang S; Wu S; Zhao G; He Y; Guo X; Zhang Z; Hou J; Ding Y; Cheng A; Wang B
    Emerg Microbes Infect; 2022 Dec; 11(1):730-740. PubMed ID: 35171086
    [No Abstract]   [Full Text] [Related]  

  • 45. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.
    Low JS; Vaqueirinho D; Mele F; Foglierini M; Jerak J; Perotti M; Jarrossay D; Jovic S; Perez L; Cacciatore R; Terrot T; Pellanda AF; Biggiogero M; Garzoni C; Ferrari P; Ceschi A; Lanzavecchia A; Sallusto F; Cassotta A
    Science; 2021 Jun; 372(6548):1336-1341. PubMed ID: 34006597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
    J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules.
    Nersisyan S; Zhiyanov A; Zakharova M; Ishina I; Kurbatskaia I; Mamedov A; Galatenko A; Shkurnikov M; Gabibov A; Tonevitsky A
    PeerJ; 2022; 10():e13354. PubMed ID: 35502206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.
    Marchan J
    J Immunol Methods; 2022 Mar; 502():113216. PubMed ID: 35007561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
    Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deciphering the immunogenic T-cell epitopes from spike protein of SARS-CoV-2 concerning the diverse population of India.
    Devi SS; Kardam V; Dubey KD; Dwivedi M
    J Biomol Struct Dyn; 2023 Apr; 41(7):2713-2732. PubMed ID: 35132938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants.
    Meyer S; Blaas I; Bollineni RC; Delic-Sarac M; Tran TT; Knetter C; Dai KZ; Madssen TS; Vaage JT; Gustavsen A; Yang W; Nissen-Meyer LSH; Douvlataniotis K; Laos M; Nielsen MM; Thiede B; Søraas A; Lund-Johansen F; Rustad EH; Olweus J
    Cell Rep; 2023 Jan; 42(1):111995. PubMed ID: 36656713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
    Martín-Galiano AJ; Díez-Fuertes F; McConnell MJ; López D
    Front Immunol; 2021; 12():732693. PubMed ID: 34899692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunoinformatics Identification of the Conserved and Cross-Reactive T-Cell Epitopes of SARS-CoV-2 with Human Common Cold Coronaviruses, SARS-CoV, MERS-CoV and Live Attenuated Vaccines Presented by HLA Alleles of Indonesian Population.
    Gustiananda M; Julietta V; Hermawan A; Febriana GG; Hermantara R; Kristiani L; Sidhartha E; Sutejo R; Agustriawan D; Andarini S; Parikesit AA
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human CD4
    Verhagen J; van der Meijden ED; Lang V; Kremer AE; Völkl S; Mackensen A; Aigner M; Kremer AN
    Clin Exp Immunol; 2021 Sep; 205(3):363-378. PubMed ID: 34061349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
    Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
    Front Immunol; 2021; 12():751869. PubMed ID: 35003063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice.
    Wang Y; Wang B; Zhao Z; Xu J; Zhang Z; Zhang J; Chen Y; Song X; Zheng W; Hou L; Wu S; Chen W
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
    Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A
    Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.
    Requena D; Médico A; Chacón RD; Ramírez M; Marín-Sánchez O
    Front Immunol; 2020; 11():2008. PubMed ID: 33013857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.
    Grifoni A; Moore E; Voic H; Sidney J; Phillips E; Jadi R; Mallal S; De Silva AD; De Silva AM; Peters B; Weiskopf D; Sette A
    Front Immunol; 2019; 10():1568. PubMed ID: 31333679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.